^
Association details:
| Biomarker: | MLH1 mutation |
|---|---|
| Cancer: | Gastric Cancer |
| Drug: | Imfinzi (durvalumab) (PD-L1 inhibitor) + Imjudo (tremelimumab) (CTLA4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
GC 2nd Line Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel Study
Excerpt:
Have one of the following targeted sequencing results 1) CD274 amplification 2) positive for mutations causing a hypermutation (PMS1, PMS2, MLH1, MLH3, MSH2, MSH3, MSH6, POLD1, POLD2, or POLE) 3) microsatellite instability (MSI high) 4) somatic exonic mutation rate-high 5) EBV positive
Trial ID:
